The Study of MicroRNA Genomics of Blood Stasis Syndrome and of Coronary Heart Disease

Phase 2

• Conditions: Coronary Heart Disease; Unstable Angina; Blood Stasis Syndrome
• Interventions: Drug: Xuesaitong soft capsule Placebo; Drug: Xuesaitong soft capsule

• Registration Number: NCT01615003
• Lead Sponsor: Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Brief Summary

In this study, typical cases of blood stasis syndrome of coronary heart disease are selected, by using microRNA chip, cDNA microarray and other bioinformatics technologies to filter and verify related miRNA and its target gene of Coronary Heart disease. Meanwhile, intervene by Xuesaitong soft capsules to investigate related miRNA and its target gene of Coronary Heart disease.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-05
• Study First Submitted: 2012-05-28
• Study First Submitted QC: 2012-06-06
• Study First Posted: 2012-06-08
• Status Verified: 2014-01
• Last Update Submitted: 2014-01-12
• Last Update Posted: 2014-01-14
• Primary Completion: 2014-07
• Study Completion: 2014-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

• Clinical diagnosis of coronary angiography unstable angina
• Clinical diagnosis of unstable angina
• Age of 30 to 75 years old
• Not use thrombolysis, dilate coronary drugs within two weeks
• Tongue dark
• Sign the consent

Exclusion Criteria

• Severe valvular heart disease
• Insulin-dependent diabetes
• mental disease
• Combined with severe liver, kidney, hematopoietic system disorder
• Patients with malignant tumors
• Pregnancy or breast-feeding women
• Recent history of trauma
• Drug allergy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
control group	Xuesaitong soft capsule Placebo	Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and placebo.
Xuesaitong soft capsule group	Xuesaitong soft capsule	Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and Xuesaitong soft capsule.

Primary Outcome Measures

Name	Time	Method
the change of Cycle threshold of relational microRNA in coronary artery disease with unstable angina	1 month	The change of Cycle threshold of relational microRNA in coronary artery disease with unstable angina by real RT-PCR.

Trial Locations

Locations (1)

Guang'an men Hispital; 🇨🇳 Beijing, Beijing, China